Glucagon and thyroid hormone (T 3 ) exhibit therapeutic potential for metabolic disease but also exhibit undesired effects. We achieved synergistic effects of these two hormones and mitigation of their adverse effects by engineering chemical conjugates enabling delivery of both activities within one precisely targeted molecule. Coordinated glucagon and T 3 actions synergize to correct hyperlipidemia, steatohepatitis, atherosclerosis, glucose intolerance, and obesity in metabolically compromised mice. We demonstrate that each hormonal constituent mutually enriches cellular processes in hepatocytes and adipocytes via enhanced hepatic cholesterol metabolism and white fat browning. Synchronized signaling driven by glucagon and T 3 reciprocally minimizes the inherent harmful effects of each hormone. Liver-directed T 3 action offsets the diabetogenic liability of glucagon, and glucagon-mediated delivery spares the cardiovascular system from adverse T 3 action. Our findings support the therapeutic utility of integrating these hormones into a single molecular entity that offers unique potential for treatment of obesity, type 2 diabetes, and cardiovascular disease.
In Brief
The therapeutic benefits of two hormones are maximized in a synthetic hybrid molecule that treats metabolic syndrome in mice by synergizing favorable effects and off-setting liabilities. 
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INTRODUCTION
Dyslipidemia, including hypercholesterolemia and hypertriglyceridemia, represents a hallmark of the metabolic syndrome and triggers a host of obesity-associated comorbidities. Liver and adipose tissues orchestrate systemic lipid homeostasis, and reciprocal dysfunction in these organs propels a vicious cycle of metabolic derangements. Hepatic steatosis is a key pathogenic factor in hepatic insulin resistance and non-alcoholic fatty liver disease (NAFLD), and perturbed cholesterol handling accelerates atherosclerosis, thus positioning dyslipidemia at the interface of type 2 diabetes (T2D) and coronary heart disease (CHD).
Inhibiting hepatic cholesterol synthesis via statins provides clinically relevant reductions in circulating cholesterol and proportionally lowers CHD risk (Nicholls et al., 2011) . However, a considerable number of patients still fail to meet target reductions in cholesterol, and a significant limitation of statin therapy is its near exclusive focus on cholesterol lowering with no benefit to glycemic control or body weight (Diamond and Ravnskov, 2015) . Therefore, a pharmacological agent that lowers cholesterol, triglycerides, glucose, hepatic fat, and body weight would offer a transformative advancement for treatment of the metabolic syndrome that should decrease mortality risk from cardiovascular events.
Thyroid hormones powerfully influence systemic metabolism through multiple pathways, with profound effects on energy expenditure, fat oxidation, and cholesterol metabolism (Mullur et al., 2014) . However, adverse side effects of thyroid hormone treatment include increased heart rate, cardiac hypertrophy, muscle wasting, and reduced bone density (Ochs et al., 2008) . Discovery of thyromimetics capable of separating lipid metabolism benefits from adverse cardiovascular effects has remained a desire. This guided attempts to rationally design small molecules with selective preference for thyroid hormone receptor beta (TRb) to treat dyslipidemia without inducing cardiac damage (Grover et al., 2003) . Second generation thyromimetics sought isoform specificity and tissue-specific function by derivatization with chemical moieties to promote tissue selectivity. These liver-targeted thyromimetics initially showed promising pre-clinical effects on handling hepatic lipids and atherogenic lipoproteins. No loss in body weight has been achieved as their mechanism of liver-targeting precludes lipolytic effects in adipose tissue (Baxter and Webb, 2009) . Therefore, selective but broadened thyroid hormone action that includes liver and adipose depots, yet spares the cardiovascular system, could offer comprehensive metabolic benefit.
Glucagon also offers many benefits for metabolic diseases independent from its glycemic effects, including lowering lipids in circulation and in the liver (Habegger et al., 2010) . The benefits of glucagon action are not solely constrained to the liver as adipose tissue is a secondary target organ for glucagon action to promote lipolysis and energy expenditure through thermogenic mechanisms (Habegger et al., 2010) . These coordinated actions demonstrate the validity of glucagon-based agonists as an antiobesity therapy, but only if the inherent diabetogenic liability can be properly controlled (Habegger et al., 2013) . We have shown that the hyperglycemic propensity of unopposed glucagon action can be effectively counterbalanced by incorporating incretin peptide activity into a glucagon-based single peptide, including unimolecular mixed agonists with glucagon-like peptide-1 (GLP-1) (Day et al., 2009 ) and/or glucose-dependent insulinotropic polypeptide (GIP) (Finan et al., 2013 (Finan et al., , 2015 .
Here, we envisioned that we could turbo-charge the livermediated lipid-lowering properties of glucagon, as well as the adipose-mediated thermogenic properties of glucagon, by introducing thyroid hormone activity into a single molecule, glucagon-based mixed agonist. We envisioned that this approach could also unleash the therapeutic utility of thyroid hormone by selectively targeting its action profile to liver and adipose tissue with a glucagon shuttle. Our vision gained momentum when we recently succeeded with an approach that allowed us to selectively, efficiently, and safely target estrogen action to the hypothalamus and pancreas using GLP-1 as a shuttle (Finan et al., 2012; Tiano et al., 2015; Schwenk et al., 2015) . We have expanded that technology to include other hormonal combinations. Here, we report glucagon-mediated selective delivery of thyroid hormone to the liver results in coordinated actions that synergize to correct hyperlipidemia, reverse hepatic steatosis, and lower body weight through liver-and fat-specific mechanisms. Importantly, the liver-directed thyroid hormone action overrides the diabetogenic liability of local glucagon action resulting in a net improvement of glycemic control, while glucagon-mediated delivery spares adverse action of thyroid hormone, notably on the cardiovascular system. degradation and C-terminally extended by 11 residues as the peptide backbone to make conjugates of glucagon and T 3 (Figure S1A) . This 40-mer glucagon analog, herein referred to as just glucagon, has a comparable in vitro activity profile at GcgR as native glucagon (Figure S1B) . We constructed three different glucagon/thyroid hormone conjugates. Two of these conjugates include the most bioactive form of thyroid hormone, 3,3 0 ,5-triiodothyronine (T 3 ). In the first conjugate, herein referred to as ''glucagon/T 3 ,'' the T 3 moiety is covalently attached to the side chain amine of the C-terminal lysine through a gamma glutamic acid (gGlu) spacer added to the carboxylate of T 3 ( Figures 1A  and S1C ). In the second conjugate, the amine of T 3 is covalently linked to the peptide through a succinate spacer at this terminal lysine (Figure S1D ). The molecular orientation of the T 3 is inverted relative to the first conjugate (glucagon/T 3 ) and is herein referred to as ''glucagon/iT 3 .'' For the third conjugate, 3,3,5 0 -triiodothyronine was used, otherwise called reverse T 3 (rT 3 ), an inactive metabolite of thyroid hormone. The rT 3 was coupled to glucagon with the same linker chemistry as used with glucagon/T 3 to generate the conjugate referred to as ''glucagon/rT 3 '' (Figure S1E) . Mass spectral analysis for each compound is presented in Figures S2A-S2D . The three different conjugates have similar activity as the parent peptide at GcgR (Figure S2E ) yet only glucagon/T 3 elicited transcriptional activity of a thyroid hormone response element in (B) levels of hepatic T 3 , plasma levels of (C) total cholesterol, (D) cholesterol bound to different lipoprotein fractions, (E) triglycerides, (F) hepatic cholesterol, (G) liver H&E staining and steatosis score, (H) hepatic mRNA profile, and (I) plasma levels of FGF21 from HFHCD-fed male C57Bl6j mice following daily s.c. injections of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 for 14 days (n = 8).
(J-N) Effects on (J) hepatic levels of T 3 , plasma levels of (K) total cholesterol, (L) cholesterol bound to different lipoprotein fractions, (M) percentage of oil-red O-positive area per total area in the aortic root, and (N) representative images of oil-red O staining of aortic root sections from HFHCD-fed LDLR À/À male mice following daily s.c. injections of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 for 14 days (n = 8).
HepG2 cells that express GcgR (Figure S2F ). This is presumably through hydrolysis in the gGlu spacer to release T 3 , which is not evident with glucagon/iT3 (Figure S2G) . Importantly, glucagon/T 3 remains intact with nearly no detectable degradation in the presence of human plasma at 37 C for up to 24 hr ( Figures S2H-S2J ).
Glucagon/T 3 Synergistically Improves Hepatic Cholesterol and Lipid Handling
To determine whether glucagon-mediated delivery of T 3 can reverse dyslipidemia and hepatic steatosis in metabolically compromised mice, we administered the glucagon/T 3 conjugates, along with mono-agonist controls, to mice maintained on a highfat, high-cholesterol diet (HFHCD). After chronic treatment, the amount of T 3 observed in the liver increased following treatment with glucagon/T 3 and matches that observed with T 3 mono-therapy ( Figure 1B ). Liquid chromatography-mass spectrometry (LC-MS) was used to quantify the amount of T 3 that accumulated in the liver after chronic treatment, thus it is confirmed that native T 3 is released from the conjugate. Glucagon/T 3 lowered levels of total plasma cholesterol in a dose-dependent manner with an onset as early as 4 days of treatment ( Figure S3A ). At the highest dose and similar to T 3 , glucagon/T 3 reduced circulating levels of total cholesterol ( Figures 1C and S3A ) and the fraction of cholesterol bound to both low-density lipoproteins (LDL) and high-density lipoproteins (HDL) ( Figure 1D ). Glucagon/T 3 reduced circulating levels of triglycerides to a similar extent as the glucagon analog ( Figure 1E ). Glucagon/T 3 lowered hepatic cholesterol content ( Figure 1F ) and hepatocellular vacuolation ( Figure 1G ) compared to vehicle controls. Plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (Figure S3D ), urea nitrogen (Figure S3E) , and creatinine ( Figure S3F ) were unchanged. Plasma levels of ketone bodies ( Figure S3G ) and citrate synthase activity (Figure S3H) were elevated with glucagon/T 3 treatment. These beneficial effects of glucagon/T 3 on dyslipidemia were similar to the effects observed after equimolar co-administration of glucagon and T 3 ( Figures 1C-1E , S4A, and S4B), demonstrating that both constituent actions are responsible for the combined effects on lipids of the conjugate. The cholesterol lowering effect, which is mostly attributable to T 3 action, was not evident after treatment with glucagon/iT 3 or glucagon/rT 3 ( Figures S4A and S4B ). This demonstrates that the specific form of thyroid hormone and its molecular orientation are vital for eliciting the coordinated hormonal actions. The effect to lower plasma cholesterol is greater than the effect observed with equimolar treatment of two thyromimetics (GC-1 and KB-2115) selective for TRb whereas the effects on plasma triglycerides are comparable ( Figures S4C and S4D ). We therefore exclusively used glucagon/T 3 as the conjugate for preclinical assessment of coordinated glucagon and T 3 action in vivo. We analyzed the livers from these mice for genes involved in cholesterol and lipid metabolism ( Figures 1H and S3I ). Glucagon/T 3 increased the expression of key genes involved in cholesterol metabolism and uptake, fatty acid oxidation, and triglyceride cycling. Glucagon/T 3 also increased mRNA expression and plasma levels of fibroblast growth factor 21 (FGF21; Figures  1H and 1I ). These changes in lipid metabolism gene programs reflect integrated hormonal actions that resulted in decreased levels of cholesterol and lipids in circulation and in the liver.
Glucagon/T 3 Improves Lipid Handling and Ameliorates Atherosclerosis in Ldlr
To test in a murine model that more closely resembles human physiology of exaggerated dyslipidemia and to parse out cholesterol-lowering mechanisms, we used low-density lipoprotein receptor knockout mice (Ldlr
). Both the hepatic accumulation of T 3 ( Figure 1J ) and lowered plasma cholesterol following glucagon/T 3 treatment was confirmed in Ldlr À/À mice ( Figure 1K ).
The conjugate primarily lowered cholesterol stored in the very low-density lipoprotein (VLDL) and LDL fractions without influencing HDL levels ( Figure 1L ). Beyond the translational relevance, this finding indicates that complementary mechanisms independent of LDLR-mediated uptake contribute to the overall efficacy in cholesterol-lowering. Because Ldlr À/À mice display atherosclerotic plaque development and aortic lesions similar to human pathophysiology, we explored whether glucagon/T 3 can reverse atherosclerotic plaque formation in Ldlr À/À mice. In this restorative treatment paradigm, 2 weeks of treatment with glucagon/T 3 reduced atherosclerotic plaque size and lesion coverage at the aortic root compared to vehicle-treated controls ( Figures 1M and  1N ). Our results demonstrate that glucagon/T 3 improves lipid metabolism to an extent that leads to the regression of established atherosclerosis.
Glucagon Drives the Pharmacokinetics of Glucagon/T 3 and Predominantly Traffics to the Liver
To determine if the covalent attachment of T 3 to glucagon alters the pharmacokinetics of the parent molecules, we measured the plasma half-life of the administered compounds following a single bolus subcutaneous (s.c.) injection to lean rats. The pharmacokinetic profile of glucagon/T 3 more closely resembles the profile of the glucagon analog as opposed to native T 3 ( Figure S5A ). Therefore, altered pharmacokinetics are not contributing to the enhanced pharmacodynamics delivered by glucagon/T 3 . To determine the tissue selectivity of glucagon/T 3 , we labeled glucagon/T 3 with the fluorescent probe on the peptide backbone. The labeling of glucagon/T 3 (herein called glucagon*/T 3 ) did not influence in vitro GcgR activity (glucagon/T 3 EC 50 = 0.050 nM and glucagon*/T 3 EC 50 = 0.058 nM), or serum halflife ( Figure S5B ). Plasma level of glucagon*/T 3 peaked within 3 hr and was cleared by the kidneys within 24 hr ( Figure S5C ). Whereas the dye control is rapidly cleared from the liver, glucagon*/T 3 presence in the liver persisted and maintained an elevated signal even after it was completely cleared from plasma and urine (Figures 2A and 2B ). We observed that glucagon*/T 3 preferentially targets the liver ( Figure S5D ), and substantially lesser signals were detected in the pancreas, inguinal fat, and heart. This tissue accumulation pattern largely overlaps with the mRNA profile of mouse Gcgr ( Figure S5E ). Cumulatively, glucagon is the dominant constituent that determines exposure and biodistribution, with liver as the predominant site of action.
Lipid Handling Benefits Are Co-mediated by GcgR and TRb and Independent from FGF21 To exclude off-target effects and examine the contribution of each component to the lipid lowering effects, we administered glucagon/T 3 to global GcgR knockout mice (Gcgr À/À mice) as well as to liver-specific TRb knockout mice (liver-specific Thrb
). Levels of T 3 in the livers of Gcgr À/À mice were not increased relative to wild-type counterparts following glucagon/T 3 treatment ( Figure 2C ). The effects to lower cholesterol and triglycerides were absent in Gcgr À/À mice ( Figure 2D -2E) and liver-specific Thrb À/À mice ( Figure 2F -2G) compared to wild-type mice. The absence of such effects in both knockout lines demonstrates the target specificity and liver preference of glucagon/T 3 to govern the effects on cholesterol and triglyceride metabolism. Further, glucagon activity is essential for sufficient T 3 delivery and TRb is responsible for coordinating improved lipid handling. Hepatic action of FGF21 works to improve lipid metabolism in rodents (Fisher et al., 2011) and this bioactivity translates to humans (Gaich et al., 2013; Talukdar et al., 2016) . Given that glucagon/T 3 stimulated a robust expression and induction of FGF21 ( Figures 1H and 1I ) that was silenced in GcgR À/À mice ( Figure 2H ), we studied the contribution of FGF21 to (A and B) Epifluorescent signal (A) and quantified average radiant efficiency (B) in livers over time following a single s.c. injection of vehicle, unconjugated dye control, or fluorescently labeled glucagon/T 3 (glucagon*/T 3 ) at a dose of 100 nmol kg À1 in lean, chow-fed C57Bl6j mice.
(C-E and H) Effects on (C) hepatic levels of T 3 , plasma levels of (D) total cholesterol and (E) triglycerides, and (H) relative expression fgf21 in livers from HFHSD-fed global GcgR À/À male mice following daily s.c. injections of vehicle or glucagon/T 3 at a dose of 100 nmol kg À1 for 7 days (n = 7-9).
(F and G) Effects on plasma levels of (F) total cholesterol and (G) triglycerides from HFHCD-fed Alf-THRb À/À male mice following daily s.c. injections of vehicle or glucagon/T 3 at a dose of 100 nmol kg À1 for 7 days (n = 5-7).
(I and J) Effects on plasma levels of (I) total cholesterol and (J) triglycerides from HFHSD-fed global FGF21 À/À male mice following daily s.c. injections of vehicle or glucagon/T 3 at a dose of 100 nmol kg À1 for 7 days (n = 8).
(K-N) RNA-seq analysis of livers from HFHCD-fed C57BL/6j male mice (n = 4) following 14 days of treatment with vehicle, a glucagon analog, T 3 , co-administration of the glucagon analog and T 3 , and the glucagon/T 3 conjugate. (K) Overlap of genes significantly regulated (>2-fold change) by the different treatment groups compared to vehicle controls. (L) Top pathways enriched in the liver by treatment with glucagon/T 3 with associated -log10 p values (right graph) for all (blue) and uniquely (green) regulated by glucagon/T 3 . Each dot displays one significant regulated gene/transcript mapped to the pathway shown with color codes for up-(red) and downregulation (blue). (M) Comparison of the magnitude of the fold change in transcription between similar genes regulated by both T 3 alone and glucagon/T 3 . (N) Magnitude of the fold change in transcription between targets that are regulated in the same direction by co-administration compared to glucagon/T 3 . To detect for synergistic like effects, we calculated a synergy score (SS) (see the STAR Methods details) for each expressed transcript and found 208 synergistic targets. For each target the log2FC for treatment with glucagon + T 3 co-admin and glucagon/T 3 is shown. *p < 0.05, **p < 0.01, and ***p < 0.001 comparing effects following compound injections to vehicle injections within each genotype. All data are presented as mean ± SEM. See also Figure S5 .
the metabolic benefits delivered by glucagon/T 3 using germline FGF21 knockout (Fgf21 À/À ) mice. The lipid-lowering effects of glucagon/T 3 do not appear to be facilitated through FGF21 as plasma levels of cholesterol and triglycerides were decreased by glucagon/T 3 in Fgf21 À/À mice ( Figures 2I   and 2J ).
Glucagon-Targeted T 3 Adjusts Hepatic Gene Programs More Efficiently Than Individual Agonists RNA sequencing (RNA-seq) of livers revealed that glucagon/T 3 regulated the expression of 956 genes with at least a 2-fold change compared to vehicle ( Figure 2K ). Mapping identified ''steroid hormone biosynthesis'' and ''metabolic pathways'' as two functional patterns that were differentially regulated in the livers of glucagon/T 3 -treated mice relative to vehicle ( Figure 2L ). The subcategories of ''metabolic pathways'' that were enriched included many specific gene programs involved in lipid and carbohydrate metabolism ( Figure 2L ). Our analysis of the transcriptomic response also uncovered 359 genes that were regulated by T 3 alone and 242 genes that only responded to glucagon ( Figure 2K ). A total of 577 genes were similarly regulated by glucagon/T 3 and the co-administration of glucagon and T 3 ( Figure 2K ). This substantial overlap demonstrates that both glucagon-sensitive and T 3 -sensitive signaling events are being engaged in the liver by the glucagon/T 3 conjugate. The magnitude of the regulation of those T 3 -sensitive genes (that are those 359 targets identified above as T 3 -sensitive) was stronger with the conjugate compared to T 3 alone ( Figure 2M ). Indeed, we observe that the conjugate synergistically regulates gene expression of targets that are modulated by both coadministration and the conjugate ( Figure 2N ). To quantify this, we applied a synergy score (see the STAR Methods) on just those targets that are regulated in the same direction by the conjugate and co-administration. This independent analysis shows that for those 208 genes, the magnitude of regulation is conspicuously greater with the conjugate than with glucagon and T 3 co-administration, supporting the notion that cumulative targeting may translate to enhanced therapeutic impact. Interestingly, 272 genes were uniquely regulated by glucagon/T 3 , but did not respond to single or co-administration of glucagon and T 3 ( Figure 2K ), suggesting that novel signaling cues are being engaged. Sub-analysis of these uniquely regulated 272 genes largely recapitulated the pathways enriched in the 956 genes differentially expressed by glucagon/T 3 , and no new pathways were enriched within this select pool of transcripts ( Figure 2L ).
Glucagon/T 3 Improves Liver Health in Mouse Model of Nonalcoholic Steatohepatitis
Because glucagon/T 3 substantially improved hepatic fat content in mice fed HFHCD, we next explored if the conjugate could ameliorate signs of steatohepatitis in a rodent model of NAFLD-induced nonalcoholic steatohepatitis (NASH) and metabolic syndrome. Mice maintained on a choline-deficient, high-fat diet (CD-HFD) for 6 months, which has been shown to be sufficient time to develop hallmark signs of human NASH (Wolf et al., 2014) , were treated with glucagon/T 3 for 3 weeks. Glucagon/T 3 normalized serum levels of cholesterol ( Figure 3A ), lowered triglycerides ( Figure 3B ), improved blood glucose (Figure 3C) , and reduced body weight ( Figure 3D ) without affecting blood parameters or blood immune cells (Table S1 ) relative to vehicle-treated controls. Glucagon/T 3 treatment resulted in a substantial lowering of serum ALT concentrations ( Figure 3E ), suggesting an improvement in liver damage, which was confirmed by macroscopic and histological analysis ( Figure 3F ). H&E staining and Sudan red staining of liver sections illustrated decreased steatosis by glucagon/T 3 , including a reduction in the overall area covered by Sudan red positive lipid droplets, ballooned hepatocytes, and satellitosis ( Figures 3F and 3G ). Although only relatively mild pericellular fibrosis was observed in livers of vehicle-treated mice, virtually no signs of fibrosis were observed in livers from mice treated with glucagon/T 3 ( Figure 3F ).
Glucagon/T 3 Lowers Body Weight By Increasing Energy Expenditure
Because both glucagon (Habegger et al., 2013) and T 3 (Silva, 2006) have been reported to increase energy expenditure and decrease body fat, we explored the weight-lowering capacity of glucagon/T 3 in diet-induced obese (DIO) mice maintained on a high-fat, high-sugar diet (HFHSD). Glucagon/T 3 dose-dependently lowered body weight ( Figure S3B ). At a dose that is sub-threshold for glucagon or T 3 to lower body weight, a 10% absolute decrease from baseline was observed after a week of treatment with glucagon/T 3 ( Figure 4A ). At a dose with minimal effects on body weight, glucagon/T 3 lowered cholesterol (Figure S3A ), thus demonstrating weight-independent effects on plasma lipids. Neither of the other conjugates or co-administration lowered body weight to the same magnitude as glucagon/T 3 ( Figures S4E and S4F ). The loss of body weight caused by glucagon/T 3 was due to a loss of fat mass, not lean mass (Figure 4B) . Food intake was increased by systemic T 3 treatment and co-administration, recapitulating the hyperphagia associated with hyperthyroidism (Kong et al., 2004 ), yet was not increased by glucagon/T 3 ( Figures 4C, S4G , and S4H). Despite the difference in energy intake, T 3 , glucagon/T 3 , and the physical mixture of glucagon and T 3 substantially increased whole-body energy expenditure ( Figures 4D, S4I , and S4J). However, the hyperphagia following treatment with T 3 compensated for increased energy expenditure, while glucagon/T 3 drove a negative energy balance resulting in a loss of body fat. Whereas systemic T 3 significantly increased ambulatory activity and rectal temperature, which paralleled the observed increase in energy expenditure, the conjugate did not cause an increase in either measure ( Figures 4E and 4F ). This again is decidedly different from their co-administration ( Figures S4K and S4L ). Glucagon/ T 3 decreased the respiratory exchange ratio (RER) without altering food intake ( Figure 4G ), demonstrating that glucagon/ T 3 shifted nutrient partitioning to promote fat utilization. Coadministration as well as the two thyromimetics also decreased RER ( Figures S4M and S4N ), but co-administration concomitantly increased food intake. Similar to the lack of cholesterol and triglyceride lowering effects observed in Gcgr À/À mice, the effects of glucagon/T 3 to lower body weight ( Figure 4H ), enhance energy expenditure (Figure 4I) , and promote fat utilization ( Figure 4J ) were likewise absent in Gcgr À/À mice. Here, in the absence of the GcgR cellular gateway, the covalent attachment of T 3 to glucagon inactivates thyroid hormone pharmacology and enhanced metabolic efficacy is not observed.
Glucagon/T 3 Induces the Browning of Inguinal White Fat
Based on the indirect calorimetry results, the low level of trafficking to inguinal white adipose tissue (iWAT) ( Figure S5D ) and the presence of GcgR in white adipose tissue (WAT) (Burcelin et al., 1995) , albeit at a level that is fractional compared to the liver (Figures S5E), we next tested the in vivo effects of glucagon/T 3 on iWAT and thermogenesis. Although the levels of T 3 residing in iWAT are below the limits of detection in a basal state, chronic treatment with glucagon/T 3 delivered a detectable amount of T 3 in iWAT, as did treatment with T 3 ( Figure 5A ). The conjugate increased the multilocular nature of iWAT and reduced adipocyte size to a similar extent as systemic T 3 whereas glucagon alone had negligible effects at this dose ( Figure 5B ). Much like T 3 itself, glucagon/T 3 turned on thermogenic gene programs in iWAT ( Figure 5C ) and triggered an increase of uncoupling protein-1 (UCP-1) immunoreactivity in iWAT ( Figure 5D ). However, the effects of glucagon/T 3 to induce UCP-1 are of lesser magnitude than T 3 itself. Glucagon/T 3 had minimal effects on gene profile changes in brown adipose tissue (BAT) (data not shown), which is consistent with reports of a lack of direct thermogenic effects on BAT by pharmacological glucagon (Dicker et al., 1998) and thyromimetics (Lin et al., 2015) . To test whether the observed iWAT browning and beige fat thermogenesis is dispensable for the effects on body and energy expenditure driven by glucagon/T 3 , we tested the conjugate in Ucp1 knockout mice (Ucp1
). The body weight lowering of glucagon/T 3 was blunted, but not completely silenced in Ucp1 À/À mice compared to wild-type controls ( Figure 5E ). Likewise, the magnitude of the shift in RER ( Figure 5F ) and the increase in energy expenditure ( Figure 5G ) induced by glucagon/ T 3 were diminished in Ucp1 À/À mice compared to wild-type mice. This attenuation shows UCP1-dependency yet indicates that other mechanisms contribute additional benefits. Hepatic action of glucagon/T 3 results in an increase in FGF21, which may convey some of benefits on energy metabolism. To determine the FGF21 contribution, we tested the glucagon/T 3 conjugate in Ffg21 À/À mice. Like Ucp1 À/À mice, the body weight lowering potency of glucagon/T 3 was diminished, but not completely lost in Fgf21 À/À mice relative to wild-type controls ( Figure 5H ). The decreased RER appears magnified in Fgf21
mice compared to wild-type controls ( Figure 5I ) yet the increase *p < 0.05 and ***p < 0.001 comparing effects following compound injections to vehicle injections. All data are presented as mean ± SEM. See also Table S1. in energy expenditure observed in wild-type mice is not as pronounced in Fgf21 À/À mice ( Figure 5J ).
Concurrent T 3 Activity Neutralizes the Diabetogenic Action Profile of Glucagon
The therapeutic utility glucagon for chronically treating obesity is compromised by its promotion of hepatic glucose production. Therefore, we tested whether targeted T 3 action could counteract the adverse effects of glucagon on glycemic control in DIO mice. The addition of the T 3 moiety to glucagon dampened acute hyperglycemia ( Figure 6A ), improved acute glucose tolerance ( Figure 6B ), and dose-dependently prevented the development of glucose intolerance or hyperglycemia after chronic treatment ( Figures 6C and S3C ), which were evident with glucagon treatment alone. Chronic treatment with the ancillary glucagon and T 3 combination therapies all resulted in improved glycemia relative to vehicle controls as well, yet glucagon/T 3 outperformed all of these treatments (Figures S4O and S4P) . The improved glucose tolerance after chronic treatment with glucagon/T 3 was lost in Gcgr À/À mice, liver-specific Figure S6D ). Glucagon/T 3 improved insulin sensitivity ( Figure 6D ) and lowered plasma levels of insulin ( Figure 6E ). We used a pyruvate tolerance test as an indirect measure of hepatic glucose output. Glucagon worsened pyruvate tolerance whereas T 3 substantially improved the effect. The attached T 3 moiety on glucagon/T 3 was capable of completely offsetting the gluconeogenic effects of glucagon ( Figure 6F ). Furthermore, the attached T 3 moiety, but not as a co-administration, prevented the glucagon-mediated increase in RER, thus limiting the shift to more carbohydrate utilization that is evident with the glucagon alone ( Figures 6G and S4Q ). This appears to be a direct result of the incorporated T 3 action to lessen the surge in hepatic glucose production combined with increased fatty acid utilization induced by the glucagon component, as evident by the acute decrease in circulating free fatty acids induced by glucagon alone and glucagon/T 3 ( Figure 6H ). Both gluconeogenic gene programs and glycolytic gene programs were increased by glucagon/T 3 in the liver ( Figure 6I ). These opposing forces suggest glucose futile cycling is involved. The gluconeogenic actions of glucagon are partly governed by engaging the peroxisome proliferator receptor gamma coactivator-1 (PGC-1) axis (Herzig et al., 2001), acting (E) cumulative locomotor activity, (F) rectal temperature, and (G) average diurnal RER from HFHSD-fed male C57Bl6j mice following daily s.c. injections of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 for 7 days (n = 8).
(H-J) Effects on (H) body weight change, (I) longitudinal energy expenditure, and (J) average diurnal RER from HFHSD-fed global GcgR À/À male mice or wild-type controls following daily s.c. injections of vehicle or glucagon/T 3 at a dose of 100 nmol kg À1 for 7 days (n = 7-9).
*p < 0.05, **p < 0.01, and ***p < 0.001 comparing effects following compound injections to vehicle injections within comparable genotypes. All data are presented as mean ± SEM. See also Figures S3 and S4.
to increase PGC-1a levels and repress PGC-1b levels. Herein, we show that concurrent T 3 action within the glucagon/T 3 conjugate mitigates the glucagon-mediated increase in Pgc1a mRNA levels and simultaneously prevents the glucagon-mediated suppression of Pgc1b mRNA levels ( Figure 6J ). Both glucagon and glucagon/T 3 increase the phosphorylation of protein kinase A (PKA) in livers of acutely treated mice to a comparable level whereas T 3 alone has no influence ( Figure 6K ). CREB is intermediary to PKA and the PGC-1 axis and governs the transcription of Pgc1a, the PGC-1 member responsible for promoting gluconeogenic machinery (Herzig et al., 2001) . Interestingly, we see that glucagon-mediated phosphorylation of CREB was reduced with glucagon/T 3 as well as with co-administration compared to glucagon alone (Figures 6K and S6E) . This indicates that concomitant T 3 action blunts distal glucagon signaling and aligns with the dampened Pgc1a mRNA levels, whereas proximal glucagon signaling is unaltered by the presence of T 3 .
Glucagon-Mediated T 3 Delivery Prevents Cardiovascular and Bone Thyrotoxicity
The therapeutic use of T 3 in obesity is undermined by deleterious effects on the cardiovascular system. Because of these concerns, as well as a low level of heart targeting that was detected by glucagon-mediated delivery ( Figure S5D ), we assessed the impact of glucagon/T 3 on cardiac hypertrophy in DIO mice after chronic treatment (all echocardiography parameters in Table  S2 ). High-dose T 3 mono-therapy reduced heart rate ( Figure 7A ) and increased respiration rate ( Figure 7B ), whereas glucagon/ T 3 had no effect on either parameter. At a lower dose that still provides lipid improvements without body weight improvements ( Figures S3A and S3B) , T 3 elevated heart rate ( Figure S7A ) and (B) iWAT H&E staining, (C) iWAT mRNA expression of select targets, and (D) UCP-1 immunoreactivity in iWAT from HFHCDfed male C57Bl6j mice following daily s.c. injections of vehicle, a glucagon analog, T 3 , or glucagon/T 3 at a dose of 100 nmol kg À1 for 14 days (n = 8).
(E-G) Effects on (E) body weight change, (F) average diurnal RER, and (G) longitudinal energy expenditure from HFHSD-fed global Ucp1 À/À male mice or wild-type controls maintained at 30 C following daily s.c. injections of vehicle or glucagon/T 3 at a dose of 100 nmol kg À1 for 7 days (n = 4-7).
(H-J) Effects on (H) body weight change, (I) average diurnal RER, and (J) longitudinal energy expenditure from HFHSD-fed global Fgf21 À/À male mice or wild-type controls following daily s.c. injections of vehicle or glucagon/T 3 at a dose of 100 nmol kg À1 for 7 days (n = 4-8).
*p < 0.05, **p < 0.01, and ***p < 0.001 comparing effects following compound injections to vehicle injections. #p < 0.05, ##p < 0.01, and ###p < 0.001 comparing effects between genotypes following compound injections. All data are presented as mean ± SEM. See also Figures S3 and S4.
increased heart size ( Figure S7B ) relative to vehicle controls whereas glucagon/T 3 did not impact either measure. T 3 also reduced fraction shortening ( Figure 7C ) and ejection fraction ( Figure 7D ). Once again, the conjugate had no apparent effect on cardiac performance ( Figures 7C and 7D ). T 3 mono-therapy, but not glucagon/T 3 , increased the tibia length-corrected heart weight ( Figure 7E ). The cardiac hypertrophy observed with T 3 coincides with increased diastolic and systolic left ventricular wall thickness ( Figures 7F and 7G ), and planar cross-sectional area ( Figure 7H ), pathological processes that do not occur with glucagon/T 3 treatment. T 3 increased the expression of T 3 -sensitive genes ( Figure S7C ) and hypertrophic gene markers (Figure S7D ) in the whole heart, which were not regulated by glucagon/T 3 . T 3 -treated mice displayed marked histopathological features of thyrotoxic cardiomyopathy, including larger cardiomyocytes, increased fat deposition, and infiltration of fibroblast and inflammatory cell into interstitial tissue ( Figure 7H ). Marked cell death was detectable in the hearts of T 3 -treated mice, including both single cell necrosis as well as larger infarction. None of these manifestations of thyrotoxicity were detectable following treatment with the glucagon/T 3 conjugate at the same molar dose. We also examined the effects of the conjugate on hypothalamic-pituitary-thyroid (HPT) feedback regulation. T 3 but not the conjugate increased circulating levels of T 3 ( Figure S7E ). Circulating levels of thyroxine were further reduced by T 3 than by glucagon/T 3 ( Figure S7F ). Despite these changes, serum levels of thyroid-stimulating hormone (TSH) (Figure S7G ) and hypothalamic expression of thyroid releasing hormone (Trh) (Figure S7H) were not affected by any treatment in this setting. (B-F) Effects on (B) acute (6 hr after therapy) and (C) chronic (after 7 days of therapy) intraperitoneal glucose tolerance (1.5 g kg À1 ), (D) intraperitoneal insulin tolerance (0.75 IU kg À1 ), (E) plasma levels of insulin, and (F) intraperitoneal pyruvate tolerance (1.5 g kg À1 ) at the indicated days from HFHSD-fed male C57Bl6j mice following daily s.c. injections of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 (n = 8).
(G) Acute effects on RER from HFHSD-fed male C57Bl6j mice immediately following a s.c. injection of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 (n = 8).
(H) Effects on plasma levels of free fatty acids from HFHSD-fed male C57Bl6j mice following a single s.c. injection of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 (n = 8).
(I and J) Effects on hepatic mRNA expression of (I) select targets indicative of glucose metabolism and (J) the PGC-1 axis from HFHCD-fed male C57Bl6j mice following daily s.c. injections of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 for 14 days (n = 8).
(K) Acute effects on levels of phosphorylated PKA and CREB normalized to GAPDH in livers of lean C57Bl6j mice 15 min following a s.c. injection of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 (n = 8).
*p < 0.05, **p < 0.01, and ***p < 0.001 comparing effects following compound injections to vehicle injections. #p < 0.05, ##p < 0.01, and ###p < 0.001 comparing effects between glucagon and glucagon/T 3 injections. All data are presented as mean ± SEM. See also Figures S3, S4 , and S6.
Because some thyromimetics can negatively impact bone metabolism, we examined the effects on bone density in lean mice following chronic treatment with T 3 and glucagon/T 3 . At a dose of glucagon/T 3 that achieves both body weight lowering and lipid lowering advantages ( Figures S3A-S3C ), glucagon/T 3 did not affect bone volume ( Figures 7I and 7J ) or markers of bone turnover (Figures S7I and S7J) . T 3 , however, substantially reduced bone volume (Figures 7I and 7J) . Like measures on cardiac performance and HPT regulation, the diminished of effects on bone turnover observed with glucagon/T 3 demonstrates that we have improved the therapeutic window of T 3 through its covalent attachment to glucagon and the subsequent preferential delivery to the liver.
DISCUSSION
The beneficial functions of thyroid hormone on systemic metabolism are largely aligned with chronic actions of glucagon on lipid metabolism and body weight. Here, we show that by using glucagon as a targeting ligand, unbiased thyroid hormone action can be selectively guided to the liver and adipose depots, where synergistic benefits on lipid metabolism and adiposity are unleashed. Importantly, we can uncouple these metabolic benefits from deleterious effects on the cardiovascular system and bone turnover that would otherwise arise from systemic thyroid hormone action. Furthermore, the liver-specific effects of thyroid hormone action counteract the diabetogenic effects of glucagon action, completing mutual cancellation of the inherent limitations of each hormone.
Individual TR and GcgR activation in the liver favorably influence lipid homeostasis by both overlapping and independent mechanisms (Habegger et al., 2010; Sinha et al., 2014). We show that glucagon and T 3 signaling pathways converge to reverse hypercholesterolemia through pleotropic mechanisms. The observed synergism and reciprocal regulation of certain gene targets offer clues to molecular underpinnings that could be mediating many of the responses. Glucagon/T 3 increased the expression of Ldlr, demonstrating that conventional cholesterol uptake mechanisms are being engaged and aligned with classical actions of glucagon on hepatic cholesterol metabolism. However, the preserved efficacy in Ldlr À/À mice suggests nontraditional mechanisms for cholesterol reabsorption by the liver are contributing to the observed effects, which overlaps with studies of T 3 in Ldlr À/À mice (Lin et al., 2012) . The fact that we find less cholesterol deposited in the liver yet increased markers of conventional and reverse cholesterol uptake suggests that we are stimulating localized conversion to bile acids. Additionally, coordinated glucagon and T 3 signaling results in increased induction of fgf21 in the liver and elevated FGF21 presence in circulation, which itself has many pharmacological benefits on lipid and energy metabolism (Kharitonenkov and Adams, 2013) . Glucagon and T 3 independently complement FGF21 action and many of their actions on systemic metabolism require FGF21 (Habegger et al., 2013; Domouzoglou et al., 2014) . Glucagon and thyroid hormone have individually been shown to have beneficial effects on hepatic triglyceride metabolism (Sinha et al., 2012; Penhos et al., 1966) . We show that glucagonmediated targeting of T 3 effectively removes fat deposition in the liver more potently than either agent alone without worsening insulin sensitivity or promoting hyperthermia in mice fed obesogenic diets. In addition, glucagon/T 3 therapy improved liver function, steatosis, and the mild fibrosis evident in mice fed a diet prone to inducing NASH. These effects are analogous to a (E) heart weight to tibia length ratio, left ventricular internal diameter at the end of (F) diastole and (G) systole, and (H) H&E staining of heart cross sections from HFHSD-fed male C57Bl6j mice following daily s.c. injections of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg À1 (n = 8) for 28 days.
(I and J) Effects on (I) bone volume and (J) representative 3D reconstructions of lumbar vertebrae L5 from lean C57Bl6j mice following a s.c. injection of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 25 nmol kg À1 for 14 days (n = 8).
*p < 0.05, **p < 0.01, and ***p < 0.001 comparing effects following compound injections to vehicle injections. All data are presented as mean ± SEM. See also Figure S7 and Table S2. liver-targeted chemical uncoupler that showed beneficial results in rodent models of NAFLD (Perry et al., 2013) . The secondary effects of glucagon/T 3 on adipose tissue and the associated modest weight-lowering efficacy will only further support alleviating disease symptoms of NASH, as our preliminary data demonstrate. We speculate that a glucagon/T 3 co-agonist could have a future application in NASH, a disease for which an effective treatment is currently lacking (Schwenger and Allard, 2014). Coordinated thyroid hormone action at the liver is appropriately positioned to counteract the hyperglycemic effects of glucagon by a mechanism different from what we achieved previously with integrated GLP-1 action (Day et al., 2009; Finan et al., 2015) . Much of the glucagon-opposing actions of GLP-1 on glycemia are mediated through effects in other tissues, notably in the pancreas and central nervous system. Here, we direct T 3 as a specific pharmacological agent to the liver in order to directly counteract the localized glucose production induced by glucagon. The addition of thyroid hormone action lessens the acute rise in blood glucose that is otherwise seen with unopposed glucagon administration and improves glucose utilization after glucose, insulin, and pyruvate challenges that are ordinarily deteriorated after chronic glucagon treatment. These disparate effects on hepatic glucose metabolism appear to be partly governed by influencing the PGC-1 axis through differential downstream signaling from GcgR, which may also contribute to the observed benefits on hepatic lipid oxidation as our transcriptional data suggest (Finck and Kelly, 2006; Lin et al., 2005) .
The weight loss following glucagon/T 3 therapy is due to increased energy expenditure, some of which is mediated via lipolytic mechanisms and the recruitment of thermogenesiscapable adipocytes in iWAT. Both glucagon and T 3 have individually been reported to increase UCP1 activity in vivo (Bianco and Silva, 1987; Billington et al., 1991) , and here we demonstrate that the conjugate induces browning of iWAT analogous to thyromimetics (Lin et al., 2015) . Our data indicates that a percentage of the T 3 that normally accesses iWAT following systemic T 3 administration is being targeted to iWAT by glucagon/T 3 . The blunted weight-lowering effect of the conjugate in Ucp1 À/À mice underscores that the increased energy expenditure induced by glucagon/T 3 is at least in part a consequence of UCP1-dependent thermogenic mechanisms without concomitant pyrexia. In relation to a permissible effect through FGF21, the effects of FGF21 on brown fat thermogenesis and body weight do not rely on UCP-1 (Samms et al., 2015; Vé niant et al., 2015) , whereas here we show that glucagon/T 3 partially relies on UCP-1 for a maximal effect on body weight. Likewise, we show that the thermogenic effects of glucagon/T 3 are mediated through FGF21, and the body weight-lowering benefit is partially dependent on FGF21 function. This demonstrates that other body weight-lowering mechanisms independent from FGF21 action are being engaged, and we speculate that macronutrient futile cycling may be facilitating part of the effects.
Chronic hyperthyroidism evolves into cardiac malfunctions such as arrhythmias that eventually progress to irreversible, serious heart damage. This in itself has limited the therapeutic utility of thyroid hormones for treating chronic diseases not associated with deficient thyroid status and is why thyromimetics were specifically engineered to activate TRb isoforms that are not present in the cardiovascular system. We show that glucagon-mediated targeting limits cardiomyocyte entry and spares the cardiovascular system from direct thyroid hormone action. Chronic therapy with glucagon/T 3 is not associated with cardiac hypertrophy, altered ventricular function, or cardiomyocyte necrosis, all of which were observed with an equimolar treatment with T 3 and resulted in severely impaired cardiac performance. Conversely, glucagon/T 3 causes mobilization and utilization of triglycerides and cholesterol and prevents the accumulation of atherosclerotic plaques in the aortic root, all of which are vital to reduce CHD risk. Because FGF21 has been shown to protect from cardiac hypertrophy (Planavila et al., 2013) , it is plausible that the observed FGF21 induction contributes to the cardiac profile of glucagon/T 3 . Clinical testing of first generation thyromimetics revealed an unexpected finding of increased bone turnover (Ladenson et al., 2010) and deleterious effects on bone cartilage in dogs (Sjouke et al., 2014) . Although we have shown that glucagon/T 3 does not impair bone mineral density at doses where T 3 induces bone loss, we have to be mindful of these overlapping links of T 3 and FG21 to bone metabolism (Wei et al., 2012; Wang et al., 2015) as we continue development of glucagon/T 3 .
Glucagon-mediated targeting offers an alternative to designing isoform-selective thyromimetics, which has proven difficult due to structural similarities in the binding pocket of TR isoforms (Wagner et al., 2001) . Unlike other strategies for hepatic targeting of thyroid hormone action (Kelly et al., 2014; Taub et al., 2013) , glucagon-mediated targeting mimics an embellished Trojan Horse approach. The engineered co-agonism allows for coordinated polypharmacology arising from T 3 and the inherent activity of the glucagon carrier, which complements TR signaling patterns and importantly directs the T 3 payload to preferential sites of action. Secondary actions in adipose depots contribute weight-lowering mechanisms that enrich the therapeutic utility of glucagon/T 3 co-agonists. Perhaps the most compelling data are that synergistic signaling improved the otherwise narrow therapeutic index of T 3 . The next step in translational development should focus on higher mammals that more closely resemble human pathology. The quantification of relative efficacy and more in-depth safety profiling will guide timing to subsequent human study and the need for further chemical optimization. Cumulatively, the data we present support the potential therapeutic utility of pairing glucagon and thyroid hormones to a single molecule that might constitute a suitably efficacious therapy for the chronic treatment of the constellation of disorders that constitute the metabolic syndrome, including obesity, fatty liver disease, type 2 diabetes, and atherosclerosis.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Wild-Type Mice for Pharmacology Studies
For studies on lipid handling in wild-type mice (Western mice), male C57Bl/6j mice (Jackson Laboratories) were fed a atherogenic Western diet (Research Diets D12079B), which is a high-cholesterol diet (0.21% gm %) with 41% kcal from fat, 43% kcal from carbohydrates, and 17% kcal from protein. For studies on energy metabolism in obese mice (DIO mice), male C57Bl/6j mice (Jackson Laboratories) were fed a diabetogenic diet (Research Diets D12331), which is a high-sucrose diet with 58% kcal from fat 25.5% kcal from carbohydrates, and 16.4% kcal from protein. For studies on NAFLD-induced NASH, male C57Bl/6j mice were fed CD-HFD (Research Diets D050110402) for 6 months prior to initiation of treatments. All dietary challenges began at 8 weeks of age. HFHSD, and HFHCD mice were single-or group-housed on a 12:12-h light-dark cycle at 22 C with free access to food and water. Mice were maintained under these conditions for a minimum of 16 weeks before initiation of pharmacological studies and were between the ages of 6 months to 12 months old. All injections and tests were performed during the light cycle. Compounds were administered in a vehicle of 1% Tween-80 and 1% DMSO and were given by daily subcutaneous (s.c.) injections at the indicated doses at a volume of 5 ml per g body weight. Mice were randomized and evenly distributed to test groups according to body weight and body composition. If ex vivo molecular biology/histology/biochemistry analyses were performed, the entire group of mice for each treatment was analyzed and scored in a blinded fashion.
Genetically-Modified Mouse Lines
All rodent studies were approved by and performed according to the guidelines of the Institutional Animal Care and Use Committee of the Helmholtz Center Munich, University of Cincinnati, Universite de Lyon, and in accordance with guidelines of the Association for the Assessment and Accreditation of Laboratory and Animal Care (AAALAC # Unit Number: 001057) and appropriate federal, state and local guidelines, respectively.
Liver-specific Thrb À/À mice were generated by crossing Thrb flox/flox mice with Alfp-Cre mice. Thrb flox/flox ; Cre negative littermates were used as wild-type controls. Mice were maintained on the HFHCD for 8 weeks prior to initiation of treatment. A follow-up study was conducted 4 weeks after the start of the first arm to confirm the effects. The data presented is a compilation of the two independent studies. Inducible, global Gcgr À/À mice were generated by crossing Gcgr flox/flox mice with Rosa26-Cre-ERT2 (tamoxifen-inducible) mice. Design and construction of the Gcgr targeting vector and the subsequent steps to generate mice heterozygous of Gcgr flox/+ were performed by the Gene Targeted Mouse Service Core at the University of Cincinnati. Briefly, the vector was designed to ''flox'' exons 4-10 of the Gcgr gene, with the neomycin resistant gene and one loxP site being inserted in the intron upstream of exon 4 and the other loxP site in the intron downstream of exon 10. The ''floxed' region and the two homologous arms, 3.4 kb and 2.5 kb respectively, were PCR-amplified from mouse genomic DNA and cloned into the vector. The construct was sequenced and then electroporated into mouse ES cells derived from a C57Bl6 strain, and the resulting cells were subject to drug selection on media containing G418. Drug resistant clones were initially screened by PCR and further confirmed by Southern blot analysis. Correctly targeted ES cell clones were injected into albino blastocysts to generate chimeras, which were then bred with C57Bl6 female mice to obtain ES cell-derived offspring as determined by the presence of black coat color. Black mice were further analyzed by PCR for transmission of targeted Gcgr gene. The neomycin cassette was deleted by breeding with mice carrying ''Flip'' recombinase. Gcgr flox/+ mice lacking the neomycin cassette and Flip allele were selected by subsequent breeding to wild-type C57Bl6 mice. The mice were backcrossed to C57Bl6 background for 5 generations and the crossed with Rosa26-Cre-ERT2 mice (Gt(ROSA)26Sor tm1(cre/ERT2)Tyj ), obtained from the The Jackson Laboratory (Stock number #008463).
Gcgr flox/flox
; Rosa26-Cre-ERT2 mice were maintained on the HFHSD for 12 weeks prior to induction of knockdown via twice daily interaperitoneal injections with tamoxifen (1 mg in 100 ml) for 5 consecutive days. Mice that received oil injections were used as wild-type controls. Treatment with compounds were initiated after 2 weeks of washout and recovery following the last tamoxifen injection.
Global Ldlr À/À mice and wild-type littermates were purchased from Jackson laboratories and were maintained on the HFHCD for 12 weeks prior to treatment initiation. Global Ucp1 À/À mice and wild-type littermates were bred in house, housed at 30 C, and maintained on a HFHSD for 12 weeks prior to initiations of treatment. Global Fgf21 À/À mice and wild-type littermates were bred in house and maintained on a HFHSD for 12 weeks prior to initiations of treatment. All mice were single-or group-housed on a 12:12-h lightdark cycle with free access to food and water.
METHOD DETAILS Peptide Synthesis
Peptide backbones were synthesized by standard fluorenylmethoxycarbonyl (Fmoc)-based solid phase peptide synthesis using 0.1 mmol Rink amide 4-methylbenzhydrylamine (MBHA) resin (Midwest Biotech) on an Applied Biosystems 433A peptide synthesizer. The automated synthesizer utilized 20% piperidine in N-methyl-2-pyrrolidone (NMP) for N-terminal amine deprotection and diisopropylcarbodiimide (DIC)/6-CI-HOBt for amino acid coupling.
Synthesis of Glucagon/T 3 Conjugate A 1:1 molar ratio of 3, 5, 3 0 -triiodothyronine and di-tert-butyl dicarbonate was dissolved in dioxane/water (4:1,v:v) in the presence of an ice bath with an addition of 0.1 equivalent of triethylamine (TEA). The reaction was stirred for 30 min at 30 C and then at room temperature for 30 hr, during which the progress of the reaction was monitored by analytical HPLC. Upon completion, the pH of the solution was lowered to 4.0 with 0.1 M hydrochloride (HCl) acid, subsequently treated it repetitively with dichloromethane (DCM) to extract desired product. The organic phase was collected, combined and evaporated in vacuum to afford crude product Boc-T 3 -OH with good purity.
The peptide backbone synthesized contained a C-terminal N'-methyltrityl-L-lysine (Lys(Mtt)-OH) moiety, whose side chain was orthogonally deprotected by four sequential 10 min treatments with 1% trifluoroacetic acid (TFA), 2% triisopropylsilane (TIS) in DCM to expose an amine as a site for T 3 conjugation. The peptidyl-resin was then mixed with a 10-fold excess of Fmoc-LGlu-OtBu(rE) activated by 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one/N,N-diisopropylethylamine (DEPBT/DIEA) in dimethylformide (DMF) for 2 hr. The completion of the coupling was confirmed by Kaiser test, after which the resin was washed and treated with 20% piperidine in DMF to remove the Fmoc protecting group located at the side chain of the gGlu residue. Subsequently, the peptidyl-resin was reacted with a 5-fold excess of crude Boc-T 3 -OH combined with DEPBT/DIEA in DMF for 2 hr to facilitate T 3 conjugation to peptide backbone. Afterward, the resin were treated with TFA cleavage cocktail containing TFA/anisole/TIS/H 2 O (85:5:5:5) for 2 hr at room temperature to release conjugate from solid support. Cleaved and fully deprotected conjugate was precipitated and washed with chilled diethyl-ether. The crude conjugates was dissolved in 15% aqueous acetonitrile containing 15% acetic acid and purified by preparative reversed-phase HPLC utilizing a linear gradient of buffer B over buffer A (A:10% aqueous acetonitrile, 0.1% TFA; B:100% acetonitrile, 0.1% TFA) on an axia-packed phenomenex luna C18 column (250 3 21.20mm) to afford the desired conjugate with carboxyl coupling of T 3 to glucagon.
Synthesis of Glucagon/iT 3 Conjugate 3, 5, 3 0 -triiodothyronine (Chem-Impex International Inc.) was solubilized in tert-butyl acetate in the presence of 0.1 equivalent of perchloric acid (HClO 4 ). The mixture was stirred at 0 C for 2 hr and at room temperature for 14 hr. Upon completion, the mixture was washed with water and ethyl acetate, treated with 10M sodium hydroxide (NaOH) until pH of the solution reached 9. Subsequently, the mixture was extracted with DCM. The combined organic phase was dried by magnesium sulfate (MgSO 4 ) and evaporated in vacuum to obtain the desired product NH 2 -T 3 -OtBu. NH 2 -T 3 -OtBu and succinic anhydride were mixed in anhydrous DMF with 0.1 equivalent of DIEA. The reaction was stirred at room temperature for 48 hr. The OH-Suc-T 3 -OtBu product was obtained followed the same workup as described for NH 2 -T 3 -OtBu. Crude OH-Suc-T 3 -OtBu was dissolved in 15% aqueous acetonitrile containing 15% acetic acid and purified by semi-preparative reversed-phase HPLC using a linear gradient of buffer B over buffer A on an axia-packed phenomenex Luna C18 column (250 3 21.20mm).
Equimolar equivalents of HO-Suc-T 3 -OtBu, DEPBT and DIEA were solubilized in DMF and directly added to the peptidyl-resin. The reaction was gently agitated at room temperature for two hours and was monitored by Kaiser test. The peptidyl resins were treated with TFA cleavage cocktail containing TFA/anisole/tTIS/H 2 O (85:5:5:5) for 2 hr at room temperature to cleave conjugate from solid support. Cleaved conjugate was precipitated and washed with chilled diethyl-ether. The glucagon/iT 3 was dissolved and purified by reversed-phase HPLC using the condition described above.
Synthesis of Glucagon/rT 3 Conjugate A 1:1 molar ratio of 3, 3 0 , 5 0 -triiodothyronine and di-tert-butyl dicarbonate were dissolved in dioxane/water (4:1,v:v) in the presence of an ice bath with an addition of 0.1 equivalent of TEA. The reaction was stirred for 30 min at 0 C and at room temperature for another 30 hr. Upon completion, the pH of the solution was lowered to 4.0 with 0.1 M HCl, subsequently treated it repetitively with DCM to extract desired product. The organic phase was collected, combined and evaporated in vacuum to afford crude product Boc-rT 3 -OH with good purity.
The peptide backbone synthesized contained a C-terminal N'-methyltrityl-L-lysine (Lys(Mtt)-OH) moiety, whose side chain was orthogonally deprotected by four 10 min treatments with 1% TFA, 2% TIS in DCM to expose amine. The peptidyl-resin was then mixed with a 10-fold excess of Fmoc-L-Glu-OtBu (gGlu) activated by DEPBT/DIEA in DMF for 2 hr. The completion of the coupling was confirmed by Kaiser test, after which the resin was washed and treated with 20% piperidine in DMF to remove the Fmoc protecting group on the gGlu residue. Subsequently, the peptidyl-resin was reacted with a 5-fold excess of crude Boc-rT 3 -OH combined with DEPBT/DIEA in DMF for 2 hr to facilitate rT 3 conjugation to peptide backbone. Afterward, the resin were treated with TFA cleavage cocktail containing TFA/anisole/TIS/H 2 O (85:5:5:5) for 2 hr at room temperature to release conjugate from solid support. Cleaved and fully deprotected conjugate was precipitated and washed with chilled diethyl-ether. The glucagon/rT3 conjugate was dissolved and purified by reversed-phase HPLC using the same condition described above. We confirmed the molecular weights of peptide and conjugates by electrospray ionization (ESI) mass spectrometry and confirmed their character by analytical reversed-phase (HPLC in 0.1% TFA with an ACN gradient on a Zorbax C8 column (0.46 cm 3 5 cm).
Human Glucagon Receptor Activation
Each peptide or conjugate was individually tested for its ability to activate the human GcgR through a cell-based luciferase reporter gene assay that indirectly measures cAMP induction. Human embryonic kidney (HEK293) cells were co-transfected with GcgR cDNA (zeocin-selection) and a luciferase reporter gene construct fused to a cAMP response element (CRE) (hygromycin B-selection). Cells were seeded at a density of 22,000 cells per well and serum deprived for 16 hr in DMEM (HyClone) supplemented with 0.25% (vol/vol) bovine growth serum (BGS) (HyClone). Serial dilutions of the peptides were added to 96-well cell-culture treated plates (BD Biosciences) containing the serum-deprived, co-transfected HEK293 cells, and incubated for 5 hr at 37 C and 5% CO 2 in a humidified environment. To stop the incubation, an equivalent volume of Steady Lite HTS luminescence substrate reagent (Perkin Elmer) was added to the cells to induce lysis and expose the lysates to luciferin. The cells were agitated for 5 min and stored for 10 min in the dark. Luminescence was measured on a MicroBeta-1450 liquid scintillation counter (Perkin-Elmer). Luminescence data were graphed against concentration of peptide and EC 50 values were calculated using Origin software (OriginLab).
TR Transcriptional Activity
For testing of transcriptional activity HEPG2 cells were cultured in HAMF12/DEMEM medium (Biochrom), supplemented with 10 FBS. Cells were seeded at a density of 5 x10 4 cells/well in a 96 well plate. One day after seeding cells were transfect each with 0.45 ng of DR4-luciferase and TRalpha plasmids using Mefatektene (Biontex). Two days after transfection cells were stimulated with 1 mM of each compound for 10 hr. Reaction was stopped and luciferase activity was measured according to the manufactures protocol (Promega).
Plasma Stability
Each compound was incubated with phosphate buffered saline (PBS, pH = 7.4) containing 60% mouse plasma at 37 C for the duration of the study. At the time points of 6h, 24h and 72h, aliquots of the incubated solutions were withdrawn and diluted with acetonitrile to precipitate the plasma proteins, which were subsequently removed by microcentrifugation at 13,000 rpm for 5 min. The supernatant was collected and diluted for the analytical reversed-phase HPLC using a linear gradient of buffer B over buffer A (A: 10% aqueous acetonitrile, 0.1% TFA; B: 90% aqueous acetonitrile, 0.1% TFA) on a Zorbax C8 column (4.6 3 50mm).
RNA sequencing RNA-Seq Total RNAs were extracted from frozen liver samples of 4 independent mice per group (vehicle, glucagon only, T 3 only, coadministration of glucagon and T 3 and glucagon/T 3 ) using TriPure RNA reagent (Sigma). Poly-A isolation, library generation and amplification were performed according to the protocol of the mRNA-Seq Library Prep Kit (Lexogen). The cDNA libraries were then converted to 5500 W librairies using the 5500 W Conversion Primer Kit (Lexogen). The Barcoded cDNA libraries were sequenced on a SOLiD 5500xl Wildfire sequencer (Life technology). Mapping of color-coded reads on the mouse genome (mm10 assembly) was performed using the Lifescope software (Life Technologies). Reads for annotated (Ensembl) genes were counted using HtSeq. Normalization of expression levels for each gene and differential expression analysis were performed using DESeq2 (Love et al., 2014) (Bioconductor R package, false discovery rate < 5%). The synergy score (SS) was calculated as the relative fold change (FC) of (glucagon/T 3 ) compared to the maximum FC of T 3 and glucagon alone: SS = FC (glucagon/T 3 ) / max (T 3 , glucagon). Synergistic hits were selected by a SS > 1.5. To reduce noise we removed transcripts from the hit list witch do not show significant regulation p < 0.05 (BH corrected) when treated with (glucagon/T 3 ) or opposite regulation.
Pathway Enrichment
Enriched KEGG pathways were determined using the hypergeometric distribution test using MATLAB (R2015b). Significant gene regulation was determined using DESeq2. Regulated genes used for pathway enrichment were selected using a threshold of p < 0.01 and the false detection rate corrected using Benjamini & Hochberg (BH) procedure. Among significant enriched KEGG pathways, relevant pathways were manually selected.
Rodent Pharmacological and Metabolism Studies
Compounds were administered by repeated s.c. injections in the middle of the light phase at the indicated doses with the indicated durations. Co-administration of compounds was administered by single formulated injections. Body weights and food intake were measured every day or every other day after the first injection. All studies with wild-type mice were performed with a group size of n = 8 or greater using mice on a C57Bl6j background. For assessment of glucose, pyruvate, and insulin tolerance during chronic treatment, the challenge tests were performed at least 24 hr after the last administration of compounds. For compound, insulin, and glucose tolerance tests, mice were fasted for 6 hr. For pyruvate tolerance tests, overnight fasting was employed. The investigators were not blinded to group allocation during the in vivo experiments or to the assessment of longitudinal endpoints.
Body Composition Measurements
Whole-body composition (fat and lean mass) was measured using nuclear magnetic resonance technology (EchoMRI).
Indirect Calorimetry
Energy intake, energy expenditure, respiratory exchange ratio, and home-cage activity were assessed using a combined indirect calorimetry system (TSE Systems). O 2 consumption and CO 2 production were measured every 10 min for a total of up to 120 hr (after 24 hr of adaptation) to determine the respiratory quotient and energy expenditure after an initial treatment regimen. Food intake was determined continuously for the same time as the indirect calorimetry assessments by integration of scales into the sealed cage environment. Home-cage locomotor activity was determined using a multidimensional infrared light beam system with beams scanning the bottom and top levels of the cage, and activity being expressed as beam breaks.
Blood Parameters
Blood was collected at the indicated times from tail veins or after euthanasia using EDTA-coated microvette tubes (Sarstedt), immediately chilled on ice, centrifuged at 5,000 g and 4 C, and plasma was stored at -80 C. For fast liquid performance chromatography (FPLC) of cholesterol distribution in different lipoprotein fractions, fresh plasma from each treatment group was pooled (n = 6-8) and ran over two Superose 6 HR columns in tandem. Cholesterol levels in the collected fractions were determined by colorimetric assay. Plasma insulin and T 3 were quantified by an ELISA assay (Ultrasenstive Mouse Insulin ELISA and Rodent T 3 ELISA; Alpco). Plasma FGF21 was quantified by an ELISA assay (Mouse FGF21 ELISA; Millipore). Plasma cholesterol, extracted hepatic cholesterol, triglycerides, ALT, and AST were measured using enzymatic assay kits (Thermo Fisher). Plasma creatinine and blood urea nitrogen were measured using enzymatic assay kits (Abcam). Plasma free fatty acids were measured using enzymatic assay kits (Wako). All assays were performed according to the manufacturers' instructions.
Histopathology
After chronic treatment, HFHCD-fed or HFHSD-fed C57Bl6/j male mice (age) were sacrificed with CO 2 , body weight as well as heart weights and tibia length was taken during necropsy. Livers and whole hearts were embedded in paraffin using a vacuum infiltration processor TissueTEK VIP (Sakura). 3mm thick slides were cut using a HMS35 rotatory microtome (Zeiss) and H & E staining was performed. For H & E staining, rehydration was done in a decreasing ethanol series, rinsing with tapwater, 2min Mayers acid Hemalum, bluing in tapwater followed by 1min EosinY (both BioOptica). Dehydration was performed in increasing ethanol series, mounting with Pertex (Medite GmbH) and coverslips (CarlRoth Chemicals). The slides were evaluated independently using a brightfield microscope (Axioplan, Zeiss). Photos were taken using the Hamamatsu-Nanozoomer HT2.0 in 1.25x, 5x. 20x and 40x magnification. The hepatic steatosis score is defined as the unweighted sum of the three individual scores for steatosis, lobular inflammation and ballooning degeneration. Steatosis is graded by the presence of fat vacuoles in liver cells according to the percentage of affected tissue (0: < 5%; 1: 5%-33%; 2: 33%-66%; 3: > 66%). Lobular inflammation is scored by overall assessment of inflammatory foci per 200x field (0: no foci; 1: < 2 foci; 2: 2-4 foci; 3: > 4 foci). The individual score for ballooning degeneration ranges from 0 (none), 1 (few cells) to 2 (many cells). Total scores range from 0 to 8 with scores < 2 considered non-steatosis, 3 considered as borderline steatosis, 4-5 considered onset of steatosis, and > 6 considered steatosis.
Different to liver and heart, inguinal fat pad samples were embedded in paraffin using Leica embedding machine (EG1150 H) and cut in 5 mm sections using Leica Microtome (RM2255) to perform H&E staining. Samples were stained with hematoxyline for 4 min and eosinY for 2 min and fixed with Roti-Histokitt (Carl Roth) before analyzing them independently using Microscope Scope A.1 (Zeiss).
In Vivo Biodistribution Imaging
For whole body bio-distribution studies, male C57BL/6 mice (10-12 weeks of age) were housed in a controlled environment with water and chow provided ad libitum. Mice were subcutaneously injected with either a VivoTag750 labeled glucagon/T 3 conjugate (''glucagon*/T 3 ''; 100 nmoles kg -1 ), a non-reactive 750nm fluorophore (100 nmol kg -1 ; Genhance 750 Fluorescent Imaging Agent, PerkinElmer) or vehicle. After 1, 3, 6, 12, and 24 hr post injection, mice were sacrificed by cervical dislocation. Trunk blood (100 mL) was immediately collected into tubes containing 10 ml antiproteolytic cocktail (4.65 g EDTA + 92 mg aprotinin + 40,000 U heparin in 50 ml saline) for plasma preparation. Urine samples (10ml) were collected by puncturing the bladder using a syringe and a fine needle and immediately protected from degradation by adding 1ml of anti-proteolytic cocktail. Plasma and urine samples from all groups and time points were stored at 4 C for collective imaging on the same 96 well plate, 24 hr after injection and using an IVIS Spectrum instrument (Perkin Elmer). Stability of the 4 C stored samples was guaranteed by comparing the signal intensities with freshly prepared samples (data not shown). Besides blood and urine samples, organs were removed from all groups. All samples per time point were collectively imaged on the same petri dish. For data analysis, regions of interest (ROI) were drawn around the isolated organs, blood and urine spots to assess the epifluorescence signal emitted. labeled glucagon*/T 3 were corrected to the auto-fluorescent background signal of the time-matched vehicle control group.
Echocardiography
For transthoracic echocardiography, a Vevo2100 Imaging System (VisualSonics Inc., Toronto Canada) with a 30 MHz probe was used. All echocardiograms were performed on conscious animals to prevent anesthesia-related impairment of cardiac function as reported previously. Briefly, echocardiograms were obtained in parasternal long and short axis views. For accurate linear measurements of LV internal dimensions (LVID) and parasternal (LVPW) or septal (IVS) wall thicknesses, M-mode images of the heart in parasternal short-axis view at the level of the papillary muscle were acquired. Qualitative and quantitative measurements were made offline using analytical software (VisualSonics Inc.). Fractional shortening (FS) was calculated as FS% = [(LVIDd-LVIDs)/ LVIDd] x 100. Ejection fraction (EF) was calculated as EF% = 100*((LVvolD-LVvolS)/LVvolD) with LVvol = ((7.0/(2.4+LVID)*LVID 3 ). The corrected LV mass (LV MassCor) was calculated as LV MassCor = 0.8(1.053*((LVIDd+LVPWd+IVSd) 3 -LVIDd 3 )). Heart rate and respiration rate were determined from M-mode tracings, using 3 consecutive intervals.
Rectal Body Temperature
Rectal body temperature was measured in conscious mice using a high-precision thermometer (thermosensor: Almemo ZA 9040, data logger: Almemo 2290-8, Ahlborn, Holzkirchen, Germany) that was carefully inserted into the rectum. Temperature of each individual was taken by the same researcher one hour after lights-on after chronic treatment ab libitum.
Atherosclerotic Plaque Assessment
The extent of atherosclerotic lesion formation was assessed in aortic root sections of LdlrÀ/À mice that were treated with glucagon/ T 3 or vehicle for 2 weeks by staining for lipid depositions with oil-red O. Briefly, atherosclerotic lesions were measured in 4-mm transverse cryo sections of aortic roots. Images of tissue sections were taken (Leica analysis software LAS) and quantified by manually outlining the lumen boundary. Subsequently, oil red O+ areas were outlined as well and the percentage of oil-red O+ areas in relation to the total area was calculated.
Immunohistochemistry For UCP1 iWAT samples were dissected and subsequently fixed and stored in 4% paraformaldehyde. After dehydration, tissues were embedded in paraffin and cut in 5 mm sections to perform immunohistochemistry using rabbit anti-UCP1 antibody (Abcam, ab10983). Therefore, samples were de-paraffinized and microwaved in citrate buffer (pH = 6) for antigen retrieval. To quench endogenous peroxidases samples were incubated with 3% hydrogen peroxide in methanol and then blocked with Avidin D, Biotin (Vectastain ABC Kit; Vector labs) and normal goat serum (10%). Anti-UCP1 antibody (1:400) was added and incubated over night, before applying secondary anti-rabbit antibody (1:300; Vector Labs ZA0324). Vectastain ABC reagent (Vectastain ABC Kit; Vector labs) was used followed by application of SIGMAFAST 3,3 0 -Diaminobenzidine (Sigma) for signal development, and subsequent counterstaining with hematoxylin and mounting. Finally, sections were analyzed using Microscope Scope A.1 (Zeiss).
Bone Density Measurements
Lumbar vertebrae L5 were analyzed using a SkyScan 1176 micro CT (Bruker, Billerica, USA) equipped with an X-ray tube working at 50 kV/100 mA. Resolution was 9 mm, rotation step was fixed at 1
, and a 0.5 mm aluminum filter was used. For reconstruction, region of interest was defined from the middle of vertebral body, spanning 0.99 mm both direction to intervertebral discs. Trabecular bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th.), trabecular separation (Tb. Sp.), and trabecular number (Tb.N.) were determined according to guidelines by ASBMR Histomorphometry Nomenclature Committee.
Quantification of Accumulated T 3 In Liver and iWAT
The stock solutions of T 3 (Sigma Aldrich) and stable isotope-labled T 3 ([ 13 C 6 ]T3; Cambridge Isotope Laboratories) were prepared dissolving 5 mg of the standard in 100 ml of pure MeOH. T3 calibration standards that ranged in concentration from 0.5 pg/mL to 100 pg/uL were prepared from stock solution through dilution with a solvent mixture of 20% acetonitrile in water. [ 13 C 6 ]T 3 was prepared in a mixture of 20% acetonitrile in water at a concentration of 10 pg/mL. The calibration solutions as well as the internal standard solutions, were protected from light, stored at 4 C and wrapped with aluminum foil. Tissue samples were homogenized in methanol containing an antioxidant solution (ascorbic acid, citric acid, and dithiothreitol at 25 g/L in methanol) by ultrasonication (Bandelin Electronics) 2 3 20 s under cooling with ice. Liquid-liquid extraction was performed as described in (Morreale de Escobar et al., 1985) . Solid phase extraction was performed loaded the water phase into a SampliQ SPE cartridge (60 mg, 3 mL; Agilent Technologies), which were preconditioned sequentially with 3 ml of 50% a methanol in chloroform, 3 ml of pure methanol and 3 ml of water. The target compound as well as the internal standard were eluted with 0.6 ml of 0.1% formic acid in methanol. The solvent was evaporated to dryness under N 2 steam and then reconstituted in 0.3 ml of 0.1N HCl in water. The thyroid hormone derivatives were extracted back in organic solvent with 3 3 0.3 ml of ethyl acetate. The solvent was evaporated again and compounds re-dissolved in 60 ml in a mixture of 20% acetonitrile in water for instrumental analysis.
Compound separation was carried out on a nanoAcquity UHPLC system (Waters Corporation) interfaced with a quadrupole timeof-flight mass spectrometer Q-TOF2 (Waters-Micromass). The system was operated under MassLynx 4.1 software (Waters-Micromass) in QTOF-MS mode. Samples were infused at a flow rate of 5 mL/min and were monitored in positive ion electrospray mode. High purity nitrogen was used as de-solvation and auxiliary gas; argon was used as the collision gas. The de-solvation gas was set to 200 L/h at a temperature of 120 C, the cone gas was set to 50 L/h and the source temperature at 100 C. The capillary extraction and the cone voltages were set to 2.6 kV and 35 V respectively. The QTOF detector (MPC) was operated at 2100 V. The instrumentation ran in full-scan mode with the QTOF data being collected between m/z 100-1000 with a collision energy of 6 eV. The data were collected in the continuum mode with a scan time 1.5 s, interscan delay of 0.1 s. The processing of calibration and quantification data including peak integration, internal standard correction and linear regression was carried out using the QuanLynx Application Manager (Waters-Micromass).
A 5 ml volume of tissue sample was directly injected into an HSS-T3 micro-scale column: 300 mm i. d. x 150 mm length, 1.8 mm particle size (Waters Corporation) at a flow rate of 5 mL/min. The mobile phase was 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). Gradient elution was performed according to the following elution program: 0-3 min, 95% A, 5% B; 3.5 min 70% A, 30% B; 5.5-6.5 min 62% A, 38% B; 7-10 min, 60% A, 40% B; 12-13 min 100% B, 13.5-20 min 95% A, 5% B. The temperature of the HSS-T3 column was kept at 40 C.
Gene Expression Analysis
Gene expression profiling in the liver, iWAT, eWAT, BAT, and heart were performed following treatment of mice according to the treatment paradigms explained in the figure legends for each specific analsysis. For tissue collection, mice were fasted for 4 hr and treated with compounds 2 hr prior to tissue collection. Gene expression was profiled with quantitative real-time RT-PCR using either TaqMan single probes or with specifically-designed TaqMan low-density array cards. The relative expression of the selected genes was normalized to the reference gene hypoxanthine-guanine phosphoribosyltransferase (Hprt). Sequence, structure, molecular weight and GcgR activity of (A) native glucagon, (B) the glucagon analog used for creation of conjugates, (C) glucagon/T 3 , (D) glucagon/iT 3 , and (E) glucagon/rT 3 . Figure S2 . In Vivo and In Vitro Profiling of Glucagon/T 3 Character, Constituent Receptor Activity, and Stability, Related to Figure 1 Mass spectrometry confirming the identity of (A) the glucagon analog, (B) glucagon/T 3 , (C) glucagon/iT 3 , and (D) glucagon/rT 3 . Receptor activity profiles of the conjugates at (E) GcgR and (F) THR using DR4-luciferase reporter assays. (G) Effects on T3 levels in the livers of HFHSD fed C57Bl6j male mice following daily s.c. injections of vehicle (black), equimolar co-administration of the glucagon analog and T 3 (orange), glucagon/iT 3 (red), or glucagon/rT 3 (brown) at a dose of 100 nmol kg -1 for 7 days (n = 8).
QUANTIFICATION AND STATISTICAL ANALYSIS
HPLC chromatograms of glucagon/T3 incubated in human plasma at 37 C after (H) 0 hr, (I) 6 hr, and (J) 24 hr exposure. ***p < 0.001 comparing effects following compound injections to vehicle injections ) in HFHSD-fed male C57Bl6j mice following daily s.c. injections of vehicle (black) or glucagon/T 3 at a dose of 10, 25, 50 or 100 nmol kg -1 (increasing shades of blue) for 10 days (n = 8).
Effects on plasma levels of (D) ALT and AST, (E) blood urea nitrogen, (F) creatinine and (G) b-hydroxybutyrate, (H) hepatic citrate synthase activity, and (I) hepatic mRNA expression, from HFHCD-fed male C57Bl6j mice following daily s.c. injections of vehicle (black), a glucagon analog (teal), T 3 (gray), or glucagon/T 3 (blue) at a dose of 100 nmol kg -1 for 14 days (n = 8).
